Ignite Creation Date:
2025-12-25 @ 3:54 AM
Ignite Modification Date:
2026-02-23 @ 12:12 PM
Study NCT ID:
NCT00113802
Status:
TERMINATED
Last Update Posted:
2021-08-19
First Post:
2005-06-10
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia
Sponsor:
Gilead Sciences
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Waldenstrom Macroglobulinemia | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Epratuzumab (hLL2- anti-CD22 humanized antibody) | View |
| None | Waldenstrom's Macroglobulinemia | View |
| None | Waldenstrom Macroglobulinemia | View |
| None | Hematologic Disease | View |
| None | Hematologic Diseases | View |
| None | Paraproteinemias | View |
| None | Vascular Hemostatic Disorders | View |
| None | Lymphoproliferative Disorders | View |